Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245103 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL244373 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802359 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802361 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802339 | 0.88 | CHRM1 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17814911 | 0.88 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17802337 | 0.88 | CHRM1 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL244385 | 0.82 | — | — | |
| SCHEMBL3397822 | 0.82 | — | — | |
| SCHEMBL242417 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3030566-B1 | 7,8-DIHYDRO-3H-PYRAZINO[1,2-B]PYRIDAZINE-3,5(6H)-DIONE COMPOUNDS AND USES THEREOF | JANSSEN BIOPHARMA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200030328-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190314373-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10251882-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10183945-B2 | Method of preparing AZA-pyridone compounds | ALIOS BIOPHARMA, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170260189-A1 | METHOD OF PREPARING AZA-PYRIDONE COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2017-09-14 | — | — | US | disclosed |
| WO-2017156407-A1 | METHOD OF PREPARING AZA-PYRIDONE COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-1976381-A2 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080167478-A1 | Tri-Substituted 2-Benzhydryl-5-Benzlamino-Tetrahydro-Pyran-4-OL and 6-Benzhydryl-4-Benzylamino-Tetrahydro-Pyran-3-OL Analogues, and Novel 3,6-Disubstituted Pyran Derivatives | WAYNE STATE UNIVERSITY (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167478-A1 | Tri-Substituted 2-Benzhydryl-5-Benzlamino-Tetrahydro-Pyran-4-OL and 6-Benzhydryl-4-Benzylamino-Tetrahydro-Pyran-3-OL Analogues, and Novel 3,6-Disubstituted Pyran Derivatives | WAYNE STATE UNIVERSITY (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1734948-A4 | TRI-SUBSTITUED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | UNIV WAYNE STATE (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070276005-A1 | TRI-SUBSTITUED 2-BENZHYDRYL 5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6 DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276005-A1 | TRI-SUBSTITUED 2-BENZHYDRYL 5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6 DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007082292-A2 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1734948-A1 | TRI-SUBSTITUED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060122263-A1 | Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-06-08 | — | — | US | disclosed |
| WO-2005105075-A1 | TRI-SUBSTITUED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030328-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-20060122263-A1 | Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives | TPH1, TPH2, HTR4 | CHRM2 2472/4885CHRM4 1073/4885CHRM5 1360/4885 |
| US-20080167478-A1 | Tri-Substituted 2-Benzhydryl-5-Benzlamino-Tetrahydro-Pyran-4-OL and 6-Benzhydryl-4-Benzylamino-Tetrahydro-Pyran-3-OL Analogues, and Novel 3,6-Disubstituted Pyran Derivatives | TPH1, TPH2, HTR4 | CHRM2 2472/4885CHRM4 1073/4885CHRM5 1360/4885 |
| US-20170260189-A1 | METHOD OF PREPARING AZA-PYRIDONE COMPOUNDS | PNPO, ITPA, AZI2 | CHRM2 1571/4885CHRM4 672/4885CHRM5 984/4885 |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-20190314373-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-10251882-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
| US-10183945-B2 | Method of preparing AZA-pyridone compounds | PNPO, ITPA, AZI2 | CHRM2 1571/4885CHRM4 672/4885CHRM5 984/4885 |
| US-20070276005-A1 | TRI-SUBSTITUED 2-BENZHYDRYL 5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6 DISUBSTITUTED PYRAN DERIVATIVES | TPH1, TPH2, HTR4 | CHRM2 2234/4885CHRM4 1063/4885CHRM5 1281/4885 |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CHRM2 359/4885CHRM4 109/4885CHRM5 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.